301015 百洋医药
已收盘 05-28 15:00:00
资讯
新帖
简况
百洋医药（301015）披露2025年度权益分派实施公告，5月25日股价上涨0.44%
证券之星 · 05-25
百洋医药（301015）披露2025年度权益分派实施公告，5月25日股价上涨0.44%
百洋医药：新规将加速行业向学术推广转型
证券之星 · 05-25
百洋医药：新规将加速行业向学术推广转型
百洋医药（301015）披露关于实施2025年度权益分派期间百洋转债暂停转股的公告，5月21日股价下跌1.65%
证券之星 · 05-21
百洋医药（301015）披露关于实施2025年度权益分派期间百洋转债暂停转股的公告，5月21日股价下跌1.65%
百洋医药（301015）新增【人工智能】概念
证券之星 · 05-20
百洋医药（301015）新增【人工智能】概念
百洋医药（301015）披露2025年年度股东会决议公告，5月20日股价上涨0.36%
证券之星 · 05-20
百洋医药（301015）披露2025年年度股东会决议公告，5月20日股价上涨0.36%
股市必读：百洋医药（301015）5月18日董秘有最新回复
证券之星 · 05-19
股市必读：百洋医药（301015）5月18日董秘有最新回复
百洋医药：同心医疗为公司控股股东参股企业
证券之星 · 05-18
百洋医药：同心医疗为公司控股股东参股企业
百洋医药：公司持续丰富运营产品矩阵
证券之星 · 04-30
百洋医药：公司持续丰富运营产品矩阵
百洋医药（301015）2026年一季报简析：净利润同比增长45.79%，盈利能力上升
证券之星 · 04-30
百洋医药（301015）2026年一季报简析：净利润同比增长45.79%，盈利能力上升
4月29日百洋医药涨5.01%，益民创新优势混合A基金重仓该股
证券之星 · 04-29
4月29日百洋医药涨5.01%，益民创新优势混合A基金重仓该股
上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参
每日经济新闻 · 04-29
上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参
图解百洋医药年报：第四季度单季净利润同比下降103.45%
证券之星 · 04-29
图解百洋医药年报：第四季度单季净利润同比下降103.45%
百洋医药：公司运营品牌安博美的销售按经营计划有序开展
证券之星 · 04-27
百洋医药：公司运营品牌安博美的销售按经营计划有序开展
百洋医药：ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署
证券之星 · 04-27
百洋医药：ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署
百洋医药：公司目前无自建核药药房的经营计划
证券之星 · 04-27
百洋医药：公司目前无自建核药药房的经营计划
百洋医药：核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营
证券之星 · 04-20
百洋医药：核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营
股市必读：百洋医药（301015）4月17日董秘有最新回复
证券之星 · 04-20
股市必读：百洋医药（301015）4月17日董秘有最新回复
股市必读：百洋医药（301015）4月16日董秘有最新回复
证券之星 · 04-17
股市必读：百洋医药（301015）4月16日董秘有最新回复
百洋医药：公司合作药品锝[99mTc]佩昔瑞特加肽注射液无需参与国家集采即可进院销售
证券之星 · 04-16
百洋医药：公司合作药品锝[99mTc]佩昔瑞特加肽注射液无需参与国家集采即可进院销售
股市必读：百洋医药（301015）4月3日董秘有最新回复
证券之星 · 04-07
股市必读：百洋医药（301015）4月3日董秘有最新回复
加载更多
公司概况
公司名称：
青岛百洋医药股份有限公司
所属行业：
批发业
上市日期：
2021-06-30
主营业务：
青岛百洋医药股份有限公司核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营,公司深度布局创新药与创新医疗器械，聚焦骨健康、抗器官纤维化、肿瘤脑转移、心血管等前沿领域，通过投资、研发转化与产业化平台运营，构建从源头创新到临床落地的全链条产业生态。公司的主要产品是药品、医疗器械、品牌服务。
发行价格：
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":22.73,"timestamp":1779951825000,"preClose":23.37,"halted":0,"volume":4942300,"delay":0,"changeRate":-0.0274,"floatShares":526000000,"shares":526000000,"eps":0.9772,"marketStatus":"已收盘","change":-0.64,"latestTime":"05-28 15:00:00","open":23.43,"high":23.48,"low":22.49,"amount":113000000,"amplitude":0.0424,"askPrice":22.74,"askSize":66,"bidPrice":22.73,"bidSize":110,"shortable":0,"etf":0,"ttmEps":0.9772,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":5,"adr":0,"adjPreClose":23.37,"symbolType":"stock","openAndCloseTimeList":[[1779931800000,1779939000000],[1779944400000,1779951600000]],"highLimit":25.71,"lowLimit":21.03,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525624077,"isCdr":false,"pbRate":4.94,"roa":"--","peRate":23.260336,"roe":"5.11%","epsLYR":0.9,"committee":0.588667,"marketValue":11947000000,"turnoverRate":0.0094,"status":1,"floatMarketCap":11946000000},"requestUrl":"/m/hq/s/301015","defaultTab":"news","newsList":[{"id":"2638017534","title":"百洋医药（301015）披露2025年度权益分派实施公告，5月25日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638017534","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638017534?lang=zh_cn&edition=full","pubTime":"2026-05-25 18:24","pubTimestamp":1779704661,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，百洋医药报收于22.92元，较前一交易日上涨0.44%，最新总市值为120.47亿元。公司于近日披露《2025年度权益分派实施公告》。本次权益分派实施后，公司实际控制人及控股股东的减持底价将调整为4.12元/股，百洋转债转股价格也将相应调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500026385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638453540","title":"百洋医药：新规将加速行业向学术推广转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2638453540","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638453540?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:06","pubTimestamp":1779696373,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药05月25日在投资者关系平台上答复投资者关心的问题。我们认为，新规将加速行业向学术推广转型，进一步净化市场环境，凭借公司扎实的合规体系与专业化团队，不会对业务推广及新管线商业化放量产生消极影响，会有助于公司在竞争中确立优势。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500020213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637841503","title":"百洋医药（301015）披露关于实施2025年度权益分派期间百洋转债暂停转股的公告，5月21日股价下跌1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637841503","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637841503?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:58","pubTimestamp":1779357522,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，百洋医药报收于22.1元，较前一交易日下跌1.65%，最新总市值为116.16亿元。近日，青岛百洋医药股份有限公司发布《关于实施2025年度权益分派期间百洋转债暂停转股的公告》。公告显示，因实施2025年度权益分派，根据相关规定，百洋转债将于2026年5月21日至权益分派股权登记日期间暂停转股，预计于股权登记日后的第一个交易日恢复转股。转股起止日期为2023年10月20日至2029年4月13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100035263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636424578","title":"百洋医药（301015）新增【人工智能】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2636424578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636424578?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:30","pubTimestamp":1779280236,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，5月20日百洋医药新增概念。百洋医药主营业务：为医药产品生产企业提供商业化整体解决方案,涵盖品牌运营、批发配送及零售三个板块。百洋医药2026年一季报显示，一季度公司主营收入17.84亿元，同比下降3.1%；归母净利润1.24亿元，同比上升45.79%；扣非净利润1.17亿元，同比上升16.63%；负债率66.17%，投资收益-145.74万元，财务费用3048.91万元，毛利率39.48%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000040599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","161631","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636810071","title":"百洋医药（301015）披露2025年年度股东会决议公告，5月20日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636810071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636810071?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:33","pubTimestamp":1779269611,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，百洋医药报收于22.47元，较前一交易日上涨0.36%，最新总市值为118.11亿元。该股当日开盘22.66元，最高22.68元，最低21.67元，成交额达1.7亿元，换手率为1.46%。青岛百洋医药股份有限公司于近日召开2025年年度股东会，会议采用现场与网络投票相结合方式，出席会议股东及授权代表共95人，代表有表决权股份359,280,395股，占公司总股本的68.3531%。所有议案均获通过，无否决议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000033331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636033250","title":"股市必读：百洋医药（301015）5月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636033250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636033250?lang=zh_cn&edition=full","pubTime":"2026-05-19 01:55","pubTimestamp":1779126913,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，百洋医药报收于22.44元，下跌1.75%，换手率0.97%，成交量5.08万手，成交额1.13亿元。董秘最新回复投资者： 您好很关注贵公司的发展。当日关注点来自交易信息汇总：5月18日主力资金净流出430.6万元，游资资金净流入430.09万元，呈现主力与游资分歧态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900002176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636202688","title":"百洋医药：同心医疗为公司控股股东参股企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2636202688","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636202688?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:54","pubTimestamp":1779094457,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：您好很关注贵公司的发展。请问，贵公司是否持有同心医疗股份？谢谢百洋医药回复：投资者您好，同心医疗为公司控股股东参股企业，上市公司运营其全磁悬浮人工心脏产品，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800023695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631688132","title":"百洋医药：公司持续丰富运营产品矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2631688132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631688132?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:36","pubTimestamp":1777534574,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：在年报中，未发现海露，海露已经不再代理了吗？百洋医药回复：投资者您好，公司持续丰富运营产品矩阵，并致力于推进优质医药健康产品快速进入临床应用。公司运营品种请以公司公告为准，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000047162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631157856","title":"百洋医药（301015）2026年一季报简析：净利润同比增长45.79%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631157856","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631157856?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:48","pubTimestamp":1777502893,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百洋医药发布2026年一季报。截至本报告期末，公司营业总收入17.84亿元，同比下降3.1%，归母净利润1.24亿元，同比上升45.79%。本报告期百洋医药盈利能力上升，毛利率同比增幅10.22%，净利率同比增幅46.29%。去年的净利率为7.62%，算上全部成本后，公司产品或服务的附加值一般。持有百洋医药最多的基金为益民创新优势混合A，目前规模为3.51亿元，最新净值1.4318，较上一交易日上涨1.5%，近一年上涨16.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631560248","title":"4月29日百洋医药涨5.01%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631560248?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:39","pubTimestamp":1777451982,"startTime":"0","endTime":"0","summary":"证券之星消息，4月29日百洋医药涨5.01%，收盘报25.34元，换手率2.25%，成交量11.82万手，成交额2.97亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。益民创新优势混合A目前规模为3.51亿元，最新净值1.4106，较上一交易日下跌0.78%，近一年上涨16.67%。张婷在任的基金产品包括:益民优势安享混合A，管理时间为2024年5月28日至今，期间收益率为52.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900052361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537129","title":"上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631537129?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:04","pubTimestamp":1777417480,"startTime":"0","endTime":"0","summary":"丨2026年4月29日星期三丨NO.1泰格医药一季度净利润同比减少70.36%4月28日，泰格医药发布2026年一季报，公司实现营业收入18.01亿元，同比增加15.17%；实现归属于上市公司股东的净利润4904.31万元，同比减少70.36%；实现归属于上市公司股东的扣除非经常性损益的净利润1.20亿元，同比增加17.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293723254882.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293723254882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","02607","601607","159938","BMY","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631587646","title":"图解百洋医药年报：第四季度单季净利润同比下降103.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631587646","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631587646?lang=zh_cn&edition=full","pubTime":"2026-04-29 02:08","pubTimestamp":1777399682,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药2025年年报显示，当年度公司主营收入75.07亿元，同比下降7.26%；归母净利润4.75亿元，同比下降31.36%；扣非净利润3.96亿元，同比下降39.59%；其中2025年第四季度，公司单季度主营收入18.79亿元，同比下降3.65%；单季度归母净利润-174.39万元，同比下降103.45%；单季度扣非净利润-1345.45万元，同比下降129.48%；负债率66.2%，投资收益1959.74万元，财务费用1.08亿元，毛利率37.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900005976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630363187","title":"百洋医药：公司运营品牌安博美的销售按经营计划有序开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2630363187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630363187?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:48","pubTimestamp":1777276089,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月27日在投资者关系平台上答复投资者关心的问题。投资者提问：按照协议，安博美今年6月份需要销售450万瓶，能不能按期完成？百洋医药回复：投资者您好，公司运营品牌安博美的销售按经营计划有序开展，销售收入请以公司公告为准，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700024407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630631283","title":"百洋医药：ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2630631283","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630631283?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:48","pubTimestamp":1777276085,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月27日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问zap-x放射设备国内已装机几台？是否已开展诊疗工作？百洋医药回复：投资者您好，公司ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署，诊疗工作按经营计划推进中，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700024395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630836319","title":"百洋医药：公司目前无自建核药药房的经营计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630836319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630836319?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:48","pubTimestamp":1777276084,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司的核药药房是自建还是租赁合作？自建多少个，合作多少个？百洋医药回复：投资者您好，公司目前无自建核药药房的经营计划，后续合作情况请关注公司公告，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700024392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628743287","title":"百洋医药：核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2628743287","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628743287?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:51","pubTimestamp":1776675068,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药04月20日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000022337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628079349","title":"股市必读：百洋医药（301015）4月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2628079349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628079349?lang=zh_cn&edition=full","pubTime":"2026-04-20 03:00","pubTimestamp":1776625233,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百洋医药报收于26.53元，上涨1.18%，换手率2.61%，成交量13.72万手，成交额3.63亿元。董秘最新回复投资者： 2026年的医保谈判已经结束，核药作为创新药，今年还有机会进医保吗？当日关注点来自交易信息汇总：4月17日主力资金净流入1385.57万元，显示主力对个股短期关注度提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000001089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628924852","title":"股市必读：百洋医药（301015）4月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2628924852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628924852?lang=zh_cn&edition=full","pubTime":"2026-04-17 01:45","pubTimestamp":1776361511,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘，百洋医药报收于26.22元，上涨1.31%，换手率2.96%，成交量15.57万手，成交额4.06亿元。董秘最新回复投资者： 董秘您好，公司合作药品锝[99mTc]佩昔瑞特加肽注射液需要通过集采才能进入医院销售吗？当日关注点来自交易信息汇总：4月16日主力资金净流出1424.12万元，散户资金净流入1375.91万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700002916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627264091","title":"百洋医药：公司合作药品锝[99mTc]佩昔瑞特加肽注射液无需参与国家集采即可进院销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2627264091","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627264091?lang=zh_cn&edition=full","pubTime":"2026-04-16 15:00","pubTimestamp":1776322846,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司合作药品锝[99mTc]佩昔瑞特加肽注射液需要通过集采才能进入医院销售吗？百洋医药回复：投资者您好，公司合作药品锝 [99mTc] 佩昔瑞特加肽注射液无需参与国家集采即可进院销售，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600021360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625012609","title":"股市必读：百洋医药（301015）4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625012609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625012609?lang=zh_cn&edition=full","pubTime":"2026-04-07 04:02","pubTimestamp":1775505738,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，百洋医药报收于25.96元，下跌0.15%，换手率6.25%，成交量32.85万手，成交额8.89亿元。董秘最新回复投资者： 请问公司在北京门头沟有生产基地或子公司吗？交易信息汇总资金流向4月3日主力资金净流入224.96万元，占总成交额0.25%；游资资金净流入555.46万元，占总成交额0.62%；散户资金净流出780.42万元，占总成交额0.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779969124626,"stockEarnings":[{"period":"1week","weight":0.0401},{"period":"1month","weight":-0.05},{"period":"3month","weight":-0.0222},{"period":"6month","weight":0.047},{"period":"1year","weight":0.3226},{"period":"ytd","weight":-0.0097}],"compareEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0128},{"period":"6month","weight":0.0528},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0315}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"14963人(较上一季度增加8.92%)","perCapita":"35123股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52562万元","survey":" 青岛百洋医药股份有限公司核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营,公司深度布局创新药与创新医疗器械，聚焦骨健康、抗器官纤维化、肿瘤脑转移、心血管等前沿领域，通过投资、研发转化与产业化平台运营，构建从源头创新到临床落地的全链条产业生态。公司的主要产品是药品、医疗器械、品牌服务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}